# Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

> **NCT03712904** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 3 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy
- **BIOLOGICAL:** Ziv-Aflibercept

## Key facts

- **NCT ID:** NCT03712904
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-09
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-12-23
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03712904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03712904, "Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03712904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*